AndreaBozzo/ceres-open-data-index huggingface dataset:
A new prototype of an electronic jet-ventilator and its humidification
		  system

Background:
          Adequate humidification in long-term jet ventilation is a critical
				aspect in terms of clinical safety.
        
        
          Aim:
          To assess a prototype of an electronic jet-ventilator and its
				humidification system.
        
        
          Methods:
          Forty patients with respiratory insufficiency were randomly
				allocated to one of four groups. The criterion for inclusion in this study was
				respiratory insufficiency exhibiting a Murray score above 2. The four groups of
				patients were ventilated with three different respirators and four different
				humidification systems. Patients in groups A and B received superimposed
				high-frequency jet ventilation (SHFJV) by an electronic jet-ventilator either
				with (group A) or without (group B) an additional humidification system.
				Patients in group C received high-frequency percussive ventilation (HFPV) by a
				pneumatic high-frequency respirator, using a hot water humidifier for warming
				and moistening the inspiration gas. Patients in group D received conventional
				mechanical ventilation using a standard intensive care unit respirator with a
				standard humidification system. SHFJV and HFPV were used for a period of 100 h
				(4days).
        
        
          Results:
          A significantly low inspiration gas temperature was noted in
				patients in group B, initially (27.2 ± 2.5°C) and after 2 days
				(28.0 ± 1.6°C) (P < 0.05). The percentage of relative
				humidity of the inspiration gas in patients in group B was also initially
				significantly low (69.8 ± 4.1%; P < 0.05) but rose to an average
				of 98 ± 2.8% after 2 h. The average percentage across all four groups
				amounted to 98 ± 0.4% after 2 h. Inflammation of the tracheal mucosa was
				found in patients in group B and the mucosal injury score (MIS) was
				significantly higher than in all the other groups. Patients in groups A, C and
				D showed no severe evidence of airway damage, exhibiting adequate values of
				relative humidity and temperature of the inspired gas.
        
        
          Conclusion:
          The problems of humidification associated with jet ventilation can
				be fully prevented by using this new jet-ventilator. These data were sustained
				by nondeteriorating MIS values at the end of the 4-day study period in groups
				A, C and D.
Program Instruction (PI-11-06)

This Program Instruction (PI) provides instruction to states on the June 30, 2011 submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act) for the Stephanie Tubbs Jones Child Welfare Services (CWS) and Promoting Safe and Stable Families (PSSF) Programs, the Child Abuse Prevention and Treatment Act (CAPTA) State Grant Program; and the Chafee Foster Care Independence Program (CFCIP) and the Education and Training Vouchers (ETV) Program; and the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report—Title IV-B, subparts 1 and 2, CFCIP, and ETV.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525077: 1-(17-Hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl)ethane-1,2-diol

Chemical compound data from PubChem database. IUPAC Name: 1-(17-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl)ethane-1,2-diol. Molecular Formula: C21H36O3. Molecular Weight: 336.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Results from the 2014 National Survey on Drug Use and Health:  Mental Health Detailed Tables

Results from the 2014 National Survey on Drug Use and Health: Mental Health Detailed Tables is a collection of tables presenting national estimates from the National Survey on Drug Use and Health (NSDUH). These tables present information on past year mental health measures and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Tables with data on adults include measures on any mental illness (AMI), serious mental illness (SMI), moderate mental illness, low (mild) mental illness, mental health service utilization (i.e., treatment or counseling for mental health issues), suicidal thoughts and behaviors, major depressive episode (MDE), treatment for depression (among adults with MDE), and serious psychological distress (SPD). Tables with data on youths include measures on mental health service utilization, MDE, and treatment for depression (among youths with MDE). Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders (SUDs) also are presented for both adults and youths. Measures of these characteristics and behaviors are presented by a variety of demographic, geographic, and other variables. The estimates in the tables include rates of persons having the characteristics, numbers of persons with these characteristics, and corresponding standard errors. Most of these tables are trend tables presenting estimates from the 2013 and 2014 NSDUHs.
National Health and Nutrition Examination Survey (NHANES) - National Cardiovascular Disease Surveillance System

1999–2000 to 2017–2018. The National Health and Nutrition Examination Survey (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews and physical examinations. Indicators from this data source have been computed by personnel in CDC's Division for Heart Disease and Stroke Prevention (DHDSP). This was one of the datasets provided by the National Cardiovascular Disease Surveillance System and presented on DHDSP’s Data, Trends, and Maps online tool. This tool was retired in April of 2024 and this dataset will not be updated. Contact dhdsprequests@cdc.gov if you need assistance with data previously included in this dataset. The data can be plotted as trends and stratified by age group, sex, and race/ethnicity.

Updated 12/9/2025: Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.
Amiodarone hydrochloride

Amiodarone Hydrochloride is a prescription medication used to treat irregular heartbeats (arrhythmias). This generic oral tablet, available in 200 mg strength, is manufactured by Unichem Pharmaceuticals (USA), Inc. and packaged by Bryant Ranch Prepack. It belongs to the antiarrhythmic drug class and inhibits certain enzymes. This information was generated using AI and is provided for informational and research purposes only.
Problems in early diagnosis of bladder cancer in a spinal cord injury patient: Report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder

Background
          Typical symptoms and signs of a clinical condition may be absent in spinal cord injury (SCI) patients.
        
        
          Case presentation
          A male with paraplegia was passing urine through penile sheath for 35 years, when he developed urinary infections. There was no history of haematuria. Intravenous urography showed bilateral hydronephrosis. The significance of abnormal outline of bladder was not appreciated. As there was large residual urine, he was advised intermittent catheterisation. Serum urea: 3.5 mmol/L; creatinine: 77 umol/L. A year later, serum urea: 36.8 mmol/l; creatinine: 632 umol/l; white cell count: 22.2; neutrophils: 18.88. Ultrasound: bilateral hydronephrosis. Bilateral nephrostomy was performed. Subsequently, blood tests showed: Urea: 14.2 mmol/l; Creatinine: 251 umol/l; Adjusted Calcium: 3.28 mmol/l; Parathyroid hormone: < 0.7 pmol/l (1.1 – 6.9); Parathyroid hormone-related protein (PTHrP): 2.3 pmol/l (0.7 – 1.8). Ultrasound scan of urinary bladder showed mixed echogenicity, which was diagnosed as debris. CT of pelvis was interpreted as vesical abscess. Urine cytology: Transitional cells showing mild atypia. Bladder biopsy: Inflamed mucosa lined by normal urothelial cells.
          A repeat ultrasound scan demonstrated a tumour arising from right lateral wall; biopsy revealed squamous cell carcinoma. In view of persistently high white cell count and high calcium level, immunohistochemistry for G-CSF and PTHrP was performed. Dense staining of tumour cells for G-CSF and faintly positive staining for C-terminal PTHrP were observed. This patient expired about five months later.
        
        
          Conclusion
          This case demonstrates how delay in diagnosis of bladder cancer could occur in a SCI patient due to absence of characteristic symptoms and signs.
Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma

Asthma is the most common chronic childhood disease in the developed nations, and is a complex disease that has high social and economic costs. Studies of the genetic etiology of asthma offer a way of improving our understanding of its pathogenesis, with the goal of improving preventive strategies, diagnostic tools, and therapies. Considerable effort and expense have been expended in attempts to detect specific polymorphisms in genetic loci contributing to asthma susceptibility. Concomitantly, the technology for detecting single nucleotide polymorphisms (SNPs) has undergone rapid development, extensive catalogues of SNPs across the genome have been constructed, and SNPs have been increasingly used as a method of investigating the genetic etiology of complex human diseases. This paper reviews both current and potential future contributions of SNPs to our understanding of asthma pathophysiology.
Evaluation of Propylene Glycol Methyl Ether as a Potential Challenge Agent for Leak Detection of Liquid and Headspace from Closed System Drug Transfer Devices using Fourier Transform Infrared Spectroscopy

Measurement of vapors from solutions containing propylene glycol methyl ether (PGME) released inside a closed chamber were evaluated. Data used to quantify limits of detection, limits of quantification, bias, precision, and accuracy of Fourier Transform Infrared Spectroscopy (FTIR) measurements of vapors from 2.5 M PGME solutions are presented. The effects of ethanol as a component of the PGME solution were also evaluated. Liquid drops of PGME solutions and headspace vapors above PGME solutions were released to simulate leaks from Closed System Drug-Transfer Devices (CSTD)s. Using a calibration apparatus, an instrumental LOD of 0.25 ppmv and a LOQ of 0.8 ppmv were determined for PGME vapor. A LOD of 1.1 µL and a LOQ of 3.5 µL was determined for liquid aliquots of 2.5 M PGME solution released in the NIOSH chamber. Accurate quantitation of liquid leaks required complete evaporation of droplets. With the upper end of the usable quantitation range limited by slow evaporation of relatively large droplets and the lower end defined by the method LOQ, the method has a narrow quantitative range for liquid droplets. Displacement of 45 mL of vial headspace containing PGME vapor is the largest amount expected when using the draft NIOSH testing protocol. Release of an unfiltered 45 mL headspace aliquot within the NIOSH chamber was calculated to produce a concentration of 0.8 ppmv based on the Henry’s constant, which is right at the instrumental LOQ.  Therefore, the sensitivity of the method was not adequate to determine leaks of PGME vapor from a headspace release through an air filtering CSTD when using the draft NIOSH testing protocols with an FTIR analyzer.
Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT?

The lowering of high blood pressure is supposed to protect target organs from hypertensive damage. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial was designed to compare the cardioprotective properties of three antihypertensives from different classes (lisinopril, amlodipine and doxazosin) with chlorthalidone. Despite effective blood pressure lowering and a favorable metabolic profile, the doxazosin arm of the trial had a significantly higher relative risk of cardiovascular disease and heart failure compared with the chlorthalidone arm. This article speculates on possible causes for this unexpected result and suggests that the culprit may be accentuation of the vascular effects of vasopressin, which are maximized under α-adrenergic blockade. These findings may have implications for the large number of older men who receive monotherapy with α-blockers for treatment of prostatic symptoms.
Compound 527674: Butanoic acid, 2-chloro, 1-methyl-3-butenyl ester

Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 2-chlorobutanoate. Molecular Formula: C9H15ClO2. Molecular Weight: 190.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525908: N,N-Dimethyl-N'-octyl-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N,N,2-trimethyl-N'-octylpropanimidamide. Molecular Formula: C14H30N2. Molecular Weight: 226.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 Daily Vaccinations - Administered in Chicago - Historical

NOTE: This dataset has been retired and marked as historical-only.

COVID-19 vaccinations administered at sites in the City of Chicago, as reported by medical providers in Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). In contrast to some other COVID-19 vaccination datasets, this one focuses on vaccinations given within the City of Chicago, rather than necessarily those given to people who live in Chicago. 

Daily counts are shown for the total number of doses administered, first dose, and second dose, as well as cumulative totals as of that date. Initial vaccines required two doses of vaccine to be administered over a period of time specific to each vaccine brand. At least one future vaccine only required one dose to be considered fully vaccinated. While these doses completed the series, additional doses have been approved for some situations and are included in the Total Doses columns.

Vaccinations are counted based on the day the vaccine was administered.  

All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. 

Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined.  

For information about the number of vaccine doses administrated to Chicago residents and number of residents considered fully vaccinated regardless of if they were vaccinated in Chicago, see https://data.cityofchicago.org/Health-Human-Services/COVID-19-Daily-Vaccinations-Chicago-Residents/2vhs-cf6b.  

For all datasets related to COVID-19, see https://data.cityofchicago.org/browse?limitTo=datasets&sortBy=alpha&tags=covid-19. 

Data Source: Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE)
Patent AT-E399942-T1: [Translated] HYDRAULIC SYSTEM

The hydraulic system, containing master and slave cylinders, has a pressure pipe between them made from two or more segments having different wall thicknesses. The pipe can be made from a plastic material in one piece, partly from plastic and partly from metal, or from a composition material with a polymer lining. The composition material can comprise a layer of an elastic material and a layer of a traction resistant material such as woven metal and/or glass and/or carbon and/or polymer fibres. Variants of the design can comprise two pipes (31, 32) linked side by side along an axial line or by a connecting rib, or coaxial pipes one inside another.
NNDSS - Table II. Mumps to Rabies, animal

NNDSS - Table II. Mumps to Rabies, animal - 2016.  In this Table, provisional* cases of selected† notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.  The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories.
Note:
These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. 

Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. 

Footnotes:
C.N.M.I.: Commonwealth of Northern Mariana Islands. 
U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.   NP:  Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum.

 * Case counts for reporting year 2016 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. 
 † Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions.
Compound 530288: 1-Butene, 2(4)-phenyl-4(2)-trimethylsilyl

Chemical compound data from PubChem database. IUPAC Name: trimethyl(4-phenylbut-1-en-2-yl)silane. Molecular Formula: C13H20Si. Molecular Weight: 204.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527006: 4-Pentyl-2-propyl-1,3-dioxane

Chemical compound data from PubChem database. IUPAC Name: 4-pentyl-2-propyl-1,3-dioxane. Molecular Formula: C12H24O2. Molecular Weight: 200.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529533: Phenanthrene, 2,4-difluoro

Chemical compound data from PubChem database. IUPAC Name: 2,4-difluorophenanthrene. Molecular Formula: C14H8F2. Molecular Weight: 214.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399815-T1: [Translated] FLAME-RESISTANT THERMOPLASTIC FILMS AND PRODUCTION PROCESS THEREOF

A film can comprise greater than or equal to about 95 wt % thermoplastic resin and about 0.001 wt % to about 5.0 wt % sulfonate salt, based on a total weight of the film, and have a UL-94 rating of VTM-0, wherein the thermoplastic resin is selected from the group consisting of polyimide, polysulfone, and copolymers, reaction products, and combinations comprising at least one of the foregoing thermoplastic resins.
Availability of Fiscal Year (FY) 2024 Children's Justice Act Grants to States Under the Child Abuse Prevention and Treatment Act (CAPTA) as Amended by Public Law (P.L.) 115-271

This Program Instruction (PI) sets forth the eligibility requirements and the grant application procedures for FY 2024 Children's Justice Act (CJA) grants and provides the tentative State allocation table.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530415: Trimethylsilyl [acryloyl(trimethylsilyl)amino]acetate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-[prop-2-enoyl(trimethylsilyl)amino]acetate. Molecular Formula: C11H23NO3Si2. Molecular Weight: 273.48. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528205: Benzoic acid, 2-hydroxy-3,6-dimethyl, DTBS

Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-5,8-dimethyl-1,3,2-benzodioxasilin-4-one. Molecular Formula: C17H26O3Si. Molecular Weight: 306.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Respiratory Virus Response (RVR) United States Hospitalization Metrics by Jurisdiction, Timeseries – ARCHIVED

<b>Note:</b> After May 3, 2024, this dataset will no longer be updated because hospitals are no longer required to report data on COVID-19 and influenza hospital admissions, hospital capacity, or occupancy data to HHS through CDC’s National Healthcare Safety Network (NHSN). 

This dataset represents hospitalization data and metrics aggregated to country, HHS region, and state/territory. Hospitalization data are reported to CDC’s National Healthcare Safety Network, which monitors national and local trends in healthcare system stress, capacity, and community disease levels for approximately 6,000 hospitals in the United States. Data reported by hospitals to NHSN and included in this dataset represent aggregated counts and include metrics capturing information specific to hospital admissions, and inpatient and ICU bed capacity occupancy.

Data fields for new admissions of pediatric patients with confirmed COVID-19 for ages 0-4 years, 5-11 years, and 12-17 years were not required for reporting until February 2022; therefore, data for the following fields in this dataset begin on March 1, 2022 to account for delays in initial reporting of these fields:
 
adm_00_04_covid_confirmed
avg_adm_00_04_covid_confirmed
avg_adm_00_04_covid_confirmed_per_100k
adm_05_11_covid_confirmed
avg_adm_05_11_covid_confirmed
avg_adm_05_11_covid_confirmed_per_100k
adm_12_17_covid_confirmed
avg_adm_12_17_covid_confirmed
avg_adm_12_17_covid_confirmed_per_100k

Updated weekly each Friday at noon, ET.